Panel discussion

WuXi XDC Cayman Inc.
Date:April 22, 2024

Panel title

ADCs & Beyond

Panel summary

Antibody-Drug Conjugates (ADCs) are currently among the most promising drug classes in oncology due to their ability to deliver cytotoxins to specific tumor sites, combining the selectivity of antibodies and the efficacy of chemotherapeutic drugs. With the approval of trastuzumab deruxtecan (Enhertu) in 2019, we have been witnessing the soaring numbers of both preclinical and clinical ADC assets as well as a number of eye-catching investments and licensing deals in this field. What could be the development strategies for the next generation of ADCs ? What are the potentials on other bioconjugates other than typical ADCs (i.e. XDC)? Can the therapeutic areas be expanded beyond oncology? This panel would like to explore on those topics.

Speaker information


Ulf Grawunder, Board member, WuXi XDC, CEO T-CURX, Managing Partner Viopas Venture Consulting


Eric Lu, Senior Director Business Development, WuXi XDC
Frederic Levy, CSO, Debiopharm
Christoph Schäfer, CEO, CIS Pharma
Philipp Spycher, CSO, Araris Biotech
Carl Deutsch, CSO, NBE-Therapeutics, Boehringer Ingelheim

Company profile

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.